<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report" xml:lang="en">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Infect Dis</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Infect. Dis</journal-id>
      <journal-title-group>
        <journal-title>BMC Infectious Diseases</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-2334</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24725844</article-id>
      <article-id pub-id-type="pmc">3995739</article-id>
      <article-id pub-id-type="publisher-id">1471-2334-14-198</article-id>
      <article-id pub-id-type="doi">10.1186/1471-2334-14-198</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Necrotizing fasciitis caused by <italic>Haemophilus influenzae</italic> type b in a patient with rectal cancer treated with combined bevacizumab and chemotherapy: a case report</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes" id="A1">
          <name>
            <surname>Ugai</surname>
            <given-names>Tomotaka</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>harukakanata58@yahoo.co.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A2">
          <name>
            <surname>Norizuki</surname>
            <given-names>Masataro</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>masataro.norizuki@gmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A3">
          <name>
            <surname>Mikawa</surname>
            <given-names>Takahiro</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>mikawan@me.com</email>
        </contrib>
        <contrib contrib-type="author" id="A4">
          <name>
            <surname>Ohji</surname>
            <given-names>Goh</given-names>
          </name>
          <xref ref-type="aff" rid="I4">4</xref>
          <email>ohji@hm.h555.net</email>
        </contrib>
        <contrib contrib-type="author" corresp="yes" id="A5">
          <name>
            <surname>Yaegashi</surname>
            <given-names>Makito</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>myaegashi@hotmail.com</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Division of General Internal Medicine and Infectious Disease, Department of Medicine, Kameda Medical Center, Kamogawa-shi, Chiba 296-8601, Japan</aff>
      <aff id="I2"><label>2</label>Current address; Division of Hematology, Department of Medicine, Saitama Medical Center, Jichi Medical University, Amanuma-cho, Omiya, Saitama-shi, Saitama 330-8503, Japan</aff>
      <aff id="I3"><label>3</label>Current address; Department of Infectious Disease, Jichi Medical University, Shimotsuke, Tochigi 329-0498, Japan</aff>
      <aff id="I4"><label>4</label>Division of Infectious Disease, Department of Microbiology and Infectious Diseases, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan</aff>
      <pub-date pub-type="collection">
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>12</day>
        <month>4</month>
        <year>2014</year>
      </pub-date>
      <volume>14</volume>
      <fpage>198</fpage>
      <lpage>198</lpage>
      <history>
        <date date-type="received">
          <day>14</day>
          <month>2</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>9</day>
          <month>4</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2014 Ugai et al.; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2014</copyright-year>
        <copyright-holder>Ugai et al.; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.biomedcentral.com/1471-2334/14/198"/>
      <abstract>
        <sec>
          <title>Background</title>
          <p>Recently, necrotizing fasciitis has been reported in patients treated with bevacizumab, usually secondary to wound healing complications, gastrointestinal perforations, or fistula formation. The risk of invasive <italic>Haemophilus influenzae</italic> type b infection is significantly increased in immunocompromised hosts. However, necrotizing fasciitis due to <italic>Haemophilus influenzae</italic> type b in a patient treated with combined bevacizumab and chemotherapy has not been previously reported.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>A 59-year-old woman was admitted to the intensive care unit after sudden onset of fever, chills, and right thigh pain. She received chemotherapy with fluorouracil, irinotecan, and bevacizumab for colon cancer 10&#xA0;days prior to admission. The advancing erythematous margin and her worsening clinical condition prompted us to suspect necrotizing fasciitis and consult the orthopedics department for a fascia biopsy and debridement. Surgical exploration revealed a murky dishwater-colored pus exudate from the incision site and the lack of a shiny appearance of the fascia that also suggested necrotizing fasciitis. After 2&#xA0;days, the final results of the blood and exudate cultures confirmed the presence of <italic>Haemophilus influenzae</italic> type b. A diagnosis of necrotizing fasciitis due to <italic>Haemophilus influenzae</italic> type b was made. The patient required recurrent surgical debridement and drainage, but she recovered from the septic shock.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>We report a case of necrotizing fasciitis due to <italic>Haemophilus influenzae</italic> type b in a patient without injury and with rectal cancer treated with combined bevacizumab and chemotherapy. Physicians should consider invasive <italic>Haemophilus influenzae</italic> type b disease in the presence of necrotizing fasciitis in patients treated with this combined treatment modality.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>Necrotizing fasciitis</kwd>
        <kwd><italic>Haemophilus influenzae</italic> type b</kwd>
        <kwd>Bevacizumab</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>Bevacizumab is an antibody designed to inhibit vascular endothelial growth factor, which is involved in blood vessel formation, and used primarily in the cancer field for the treatment of colorectal cancer to prevent the formation of blood vessels that feed tumors. Recently, necrotizing fasciitis has been reported in patients treated with bevacizumab, including some fatal cases
[<xref ref-type="bibr" rid="B1">1</xref>]. However, necrotizing fasciitis usually develops secondary to wound healing complications, gastrointestinal perforations, or fistula formation. Here, we report a case of necrotizing fasciitis due to <italic>Haemophilus influenzae</italic> type b (Hib) in a patient without injury and with rectal cancer treated with combined bevacizumab and chemotherapy.</p>
      <sec>
        <title>Case presentation</title>
        <p>A 59-year-old woman was admitted to the intensive care unit after sudden onset of fever, chills, and right thigh pain. She had undergone low anterior resection for colon cancer 2&#xA0;years earlier. After local recurrence, she underwent radiation therapy (30&#xA0;Gy) for spinal metastasis followed by chemotherapy, which commenced 6&#xA0;months prior to admission to the intensive care unit. She received chemotherapy with fluorouracil, irinotecan, and bevacizumab 10&#xA0;days prior to admission. She did not have a history of previous injury or the presence of other risk factors for necrotizing fasciitis such as a decubitus ulcer, diabetes, or liver cirrhosis. Her medications included a 5-HT3 receptor antagonist, which is an antiemetic, and a proton pump inhibitor; however, her medications did not include non-steroidal anti-inflammatory drugs, immunosuppressive drugs, or corticosteroids.</p>
        <p>She was hypotensive, tachycardic, and tachypneic in the emergency room. The results of the physical examination were normal except for erythema in her right thigh. She had no previous injuries. Hemoglobin level was 118&#xA0;g/L with a white blood cell count of 2.1&#x2009;&#xD7;&#x2009;10<sup>9</sup> cells/L and a platelet count of 1.3&#x2009;&#xD7;&#x2009;10<sup>11</sup> cells/L. Blood urea nitrogen was 18.9&#xA0;mmol/L, creatinine was 318.2&#xA0;&#x3BC;mol/L, and C-reactive protein was 3.8&#x2009;&#xD7;&#x2009;10<sup>6</sup>&#xA0;&#x3BC;g/L. The results of other blood tests and urinalysis were normal. Computed tomography of the chest, abdomen, and pelvis showed normal results. Septic shock was suspected and managed accordingly with supportive measures, such as the use of a vasopressor and supplemental oxygen. Blood cultures were collected, and empirical treatment with meropenem (1&#xA0;g every 12&#xA0;hours) and vancomycin (1&#xA0;g daily) were initiated, adjusted to renal dysfunction. The advancing erythematous margin and her worsening clinical condition prompted us to suspect necrotizing fasciitis and consult the orthopedics department for a fascia biopsy and debridement. Surgical exploration revealed a murky dishwater-colored pus exudate from the incision site and the lack of a shiny appearance of the fascia that also suggested necrotizing fasciitis. The biopsy of the frozen section showed acute necrotizing suppurative inflammation, and extensive debridement was performed. Gram staining of the exudates from the infected site showed the presence of gram-negative rods. On the basis of all of this information, we formally diagnosed the patient with necrotizing fasciitis. On the following day, gram-negative rods were also isolated from the blood cultures. After 2&#xA0;days, the final results of the blood and exudate cultures confirmed the presence of &#x3B2;-lactamase-negative Hib that was susceptible to ampicillin, cefotaxime, ciprofloxacin, and imipenem. The histopathological findings of the debrided tissue were compatible with a diagnosis of necrotizing fasciitis due to Hib.</p>
        <p>The patient required recurrent surgical debridement and drainage, but she recovered from the septic shock. The treatment was changed to ampicillin, and she received intravenous ampicillin for a total of 51&#xA0;days because of residual intermuscular abscesses. She recovered completely and was discharged from the hospital 65&#xA0;days after admission. Necrotizing fasciitis did not recur; however, she died of metastatic colorectal cancer 6&#xA0;months after discharge.</p>
      </sec>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>Necrotizing fasciitis is a rare but life-threatening infection of the soft tissue that is characterized by rapidly spreading necrosis of the superficial fascia and subcutaneous tissue. Immunocompromised and diabetic patients are at a higher risk of developing necrotizing fasciitis
[<xref ref-type="bibr" rid="B2">2</xref>]. Although bevacizumab suppresses the immune system
[<xref ref-type="bibr" rid="B3">3</xref>], chemotherapy administered concurrently with bevacizumab is more likely to be responsible for immune suppression. This combined treatment also contributes to impaired wound healing. Furthermore, one of the pathophysiologic mechanisms of necrotizing fasciitis is subcutaneous artery thrombosis and tissue ischemia, to which bevacizumab can contribute
[<xref ref-type="bibr" rid="B4">4</xref>]. Therefore, the combined treatment modality of bevacizumab and chemotherapy is likely to place patients at an increased risk of developing necrotizing fasciitis. Despite the fact that necrotizing fasciitis is a rare complication, affecting only 1 in 5000 bevacizumab users, physicians should bear in mind the risk of necrotizing fasciitis when prescribing bevacizumab.</p>
      <p>In a comprehensive safety review conducted by the company Roche, 52 case reports of serious necrotizing fasciitis were identified that occurred between November 1997 and September 2012 in patients treated with bevacizumab for cancer
[<xref ref-type="bibr" rid="B5">5</xref>]. The majority of the patients described in case reports have had gastrointestinal perforations, fistula formation, or wound healing complications preceding the development of necrotizing fasciitis
[<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B8">8</xref>]. However, in the present case, the patient had no previous injury or risk factor for necrotizing fasciitis such as a decubitus ulcer, diabetes, or liver cirrhosis; her recent chemotherapy was her primary risk for necrotizing fasciitis. These findings suggest a possible association between necrotizing fasciitis and the recent combined treatment of chemotherapy and bevacizumab in the absence of a previous injury.</p>
      <p>It is of particular interest that Hib caused the necrotizing fasciitis in the present case. Prior to routine Hib vaccination, Hib was a well-known cause of invasive diseases, such as meningitis and pneumonia with bacteremia, in children younger than 2&#xA0;years. However, the incidence of invasive <italic>H. influenzae</italic> disease, especially among persons aged over 65&#xA0;years, and invasive non-typable <italic>H. influenzae</italic> disease has increased from 1996 to 2004
[<xref ref-type="bibr" rid="B9">9</xref>]. The risk of invasive Hib infection in adults is significantly increased by multiple myeloma and chronic renal failure
[<xref ref-type="bibr" rid="B10">10</xref>]. Other factors conferring increased risk for <italic>H. influenzae</italic> infection include underlying immunocompromising conditions such as complement deficiency, hypogammaglobulinemia, sickle cell anemia, functional asplenia, malignancy, and human immunodeficiency virus infection
[<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>]. Although the association between bevacizumab and invasive Hib infection remains unclear, we caution physicians to consider invasive Hib disease in patients treated with the combination of bevacizumab and chemotherapy.</p>
      <p>A review of the current literature resulted in only 4 reported cases of necrotizing fasciitis caused by Hib. The first reported case occurred in a 13-month-old infant
[<xref ref-type="bibr" rid="B13">13</xref>], while the second case occurred in an 81-year-old man with diabetes mellitus
[<xref ref-type="bibr" rid="B14">14</xref>]. A 64-year-old woman who developed necrotizing fasciitis of her chest wall secondary to the epiglottitis represented the third case
[<xref ref-type="bibr" rid="B15">15</xref>]. In the fourth case, a 44-year-old man developed necrotizing fasciitis of the right lower extremity after intramuscular injections of paracetamol in his right buttock
[<xref ref-type="bibr" rid="B16">16</xref>]. Including our case, all of the patients with necrotizing fasciitis due to Hib made a full recovery. Hib merits additional consideration when deciding on appropriate, empiric antimicrobial therapy as an adjunct to surgical intervention for necrotizing fasciitis, especially in immunocompromised patients treated with combined bevacizumab and chemotherapy.</p>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusions</title>
      <p>We report a case of necrotizing fasciitis due to Hib in a patient without injury and with rectal cancer treated with combined bevacizumab and chemotherapy. Physicians should consider invasive Hib disease in the presence of necrotizing fasciitis in patients treated with this combined treatment modality.</p>
    </sec>
    <sec>
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient for publication of this case report. A copy of the written consent is available for review by the Editor-in-Chief of this journal.</p>
    </sec>
    <sec>
      <title>Abbreviations</title>
      <p>Hib: <italic>Haemophilus influenzae</italic> type b.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The authors declare that they have no competing interests.</p>
      <p>All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.</p>
    </sec>
    <sec>
      <title>Authors&#x2019; contributions</title>
      <p>All authors were involved in the clinical care of the patient and acquisition and interpretation of the data. TU drafted the manuscript. All authors read and approved the final manuscript.</p>
    </sec>
    <sec>
      <title>Pre-publication history</title>
      <p>The pre-publication history for this paper can be accessed here:</p>
      <p>
        <ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2334/14/198/prepub">http://www.biomedcentral.com/1471-2334/14/198/prepub</ext-link>
      </p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Shamloo</surname>
            <given-names>BK</given-names>
          </name>
          <name>
            <surname>Chhabra</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Freedman</surname>
            <given-names>AN</given-names>
          </name>
          <name>
            <surname>Potosky</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Malin</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Weiss Smith</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Novel adverse events of bevacizumab in the US FDA adverse event reporting system database: a disproportionality analysis</article-title>
          <source>Drug Saf</source>
          <year>2012</year>
          <volume>14</volume>
          <issue>6</issue>
          <fpage>507</fpage>
          <lpage>518</lpage>
          <pub-id pub-id-type="doi">10.2165/11597600-000000000-00000</pub-id>
          <pub-id pub-id-type="pmid">22612854</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Stumvoll</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Fritsche</surname>
            <given-names>A</given-names>
          </name>
          <article-title>Necrotizing fasciitis caused by unencapsulated Haemophilus influenzae</article-title>
          <source>Clin Infect Dis</source>
          <year>1997</year>
          <volume>14</volume>
          <issue>2</issue>
          <fpage>327</fpage>
          <pub-id pub-id-type="doi">10.1086/516908</pub-id>
          <pub-id pub-id-type="pmid">9332536</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Correale</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Remondo</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Carbone</surname>
            <given-names>SF</given-names>
          </name>
          <name>
            <surname>Ricci</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Migali</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Martellucci</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Licchetta</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Addeo</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Volterrani</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Gotti</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Rotundo</surname>
            <given-names>MS</given-names>
          </name>
          <name>
            <surname>Tassone</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Sperlongano</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Abbruzzese</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Caraglia</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Tagliaferri</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Francini</surname>
            <given-names>G</given-names>
          </name>
          <article-title>Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients</article-title>
          <source>Cancer Biol Ther</source>
          <year>2010</year>
          <volume>14</volume>
          <issue>9</issue>
          <fpage>685</fpage>
          <lpage>693</lpage>
          <pub-id pub-id-type="doi">10.4161/cbt.9.9.11441</pub-id>
          <pub-id pub-id-type="pmid">20697196</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Sarani</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Strong</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Pascual</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Schwab</surname>
            <given-names>CW</given-names>
          </name>
          <article-title>Necrotizing fasciitis: current concepts and review of the literature</article-title>
          <source>J Am Coll Surg</source>
          <year>2009</year>
          <volume>14</volume>
          <issue>2</issue>
          <fpage>279</fpage>
          <lpage>288</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jamcollsurg.2008.10.032</pub-id>
          <pub-id pub-id-type="pmid">19228540</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Wong</surname>
            <given-names>J</given-names>
          </name>
          <article-title>Bevacizumab is linked to cases of necrotising fasciitis</article-title>
          <source>Lancet Oncol</source>
          <year>2013</year>
          <volume>14</volume>
          <issue>7</issue>
          <fpage>e259</fpage>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Shimada</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Nakamura</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Ishii</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Chiba</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Ishikawa</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Arisawa</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Hashimoto</surname>
            <given-names>M</given-names>
          </name>
          <article-title>A case of necrotizing fasciitis developed in a patient with recurrent rectal cancer treated with chemotherapy</article-title>
          <source>Gan To Kagaku Ryoho</source>
          <year>2013</year>
          <volume>14</volume>
          <issue>5</issue>
          <fpage>663</fpage>
          <lpage>665</lpage>
          <pub-id pub-id-type="pmid">23863596</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Gamboa</surname>
            <given-names>EO</given-names>
          </name>
          <name>
            <surname>Rehmus</surname>
            <given-names>EH</given-names>
          </name>
          <name>
            <surname>Haller</surname>
            <given-names>N</given-names>
          </name>
          <article-title>Fournier&#x2019;s gangrene as a possible side effect of bevacizumab therapy for resected colorectal cancer</article-title>
          <source>Clin Colorectal Cancer</source>
          <year>2010</year>
          <volume>14</volume>
          <issue>1</issue>
          <fpage>55</fpage>
          <lpage>58</lpage>
          <pub-id pub-id-type="doi">10.3816/CCC.2010.n.008</pub-id>
          <pub-id pub-id-type="pmid">20100690</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Sendur</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Aksoy</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Ozdemir</surname>
            <given-names>NY</given-names>
          </name>
          <name>
            <surname>Zengin</surname>
            <given-names>N</given-names>
          </name>
          <article-title>Necrotizing fasciitis secondary to bevacizumab treatment for metastatic rectal adenocarcinoma</article-title>
          <source>Indian J Pharmacol</source>
          <year>2014</year>
          <volume>14</volume>
          <issue>1</issue>
          <fpage>125</fpage>
          <lpage>126</lpage>
          <pub-id pub-id-type="doi">10.4103/0253-7613.125195</pub-id>
          <pub-id pub-id-type="pmid">24550600</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Dworkin</surname>
            <given-names>MS</given-names>
          </name>
          <name>
            <surname>Park</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Borchardt</surname>
            <given-names>SM</given-names>
          </name>
          <article-title>The changing epidemiology of invasive Haemophilus influenzae disease, especially in persons&#x2009;&gt;&#x2009;or&#x2009;=&#x2009;65&#xA0;years old</article-title>
          <source>Clin Infect Dis</source>
          <year>2007</year>
          <volume>14</volume>
          <issue>6</issue>
          <fpage>810</fpage>
          <lpage>816</lpage>
          <pub-id pub-id-type="doi">10.1086/511861</pub-id>
          <pub-id pub-id-type="pmid">17304452</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Nix</surname>
            <given-names>EB</given-names>
          </name>
          <name>
            <surname>Hawdon</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Gravelle</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Biman</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Brigden</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Malik</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>McCready</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Ferroni</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Ulanova</surname>
            <given-names>M</given-names>
          </name>
          <article-title>Risk of invasive Haemophilus influenzae type b (Hib) disease in adults with secondary immunodeficiency in the post-Hib vaccine era</article-title>
          <source>Clin Vaccine Immunol</source>
          <year>2012</year>
          <volume>14</volume>
          <issue>5</issue>
          <fpage>766</fpage>
          <lpage>771</lpage>
          <pub-id pub-id-type="doi">10.1128/CVI.05675-11</pub-id>
          <pub-id pub-id-type="pmid">22398246</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Makela</surname>
            <given-names>PH</given-names>
          </name>
          <name>
            <surname>Takala</surname>
            <given-names>AK</given-names>
          </name>
          <name>
            <surname>Peltola</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Eskola</surname>
            <given-names>J</given-names>
          </name>
          <article-title>Epidemiology of invasive Haemophilus influenzae type b disease</article-title>
          <source>J Infect Dis</source>
          <year>1992</year>
          <volume>14</volume>
          <issue>Suppl 1</issue>
          <fpage>S2</fpage>
          <lpage>S6</lpage>
          <pub-id pub-id-type="pmid">1588164</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Cordero</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Pachon</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Rivero</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Giron</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Gomez-Mateos</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Merino</surname>
            <given-names>MD</given-names>
          </name>
          <name>
            <surname>Torres-Tortosa</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Gonzalez-Serrano</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Aliaga</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Collado</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Hern&#xE1;ndez-Quero</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Barrera</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Nu&#xF1;o</surname>
            <given-names>E</given-names>
          </name>
          <article-title>Haemophilus influenzae pneumonia in human immunodeficiency virus-infected patients. The Grupo Andaluz para el Estudio de las Enfermedades Infecciosas</article-title>
          <source>Clin Infect Dis</source>
          <year>2000</year>
          <volume>14</volume>
          <issue>3</issue>
          <fpage>461</fpage>
          <lpage>465</lpage>
          <pub-id pub-id-type="doi">10.1086/313690</pub-id>
          <pub-id pub-id-type="pmid">10722428</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Collette</surname>
            <given-names>CJ</given-names>
          </name>
          <name>
            <surname>Southerland</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Corrall</surname>
            <given-names>CJ</given-names>
          </name>
          <article-title>Necrotizing fasciitis associated with Haemophilus influenzae type b</article-title>
          <source>Am J Dis Child</source>
          <year>1987</year>
          <volume>14</volume>
          <issue>11</issue>
          <fpage>1146</fpage>
          <lpage>1148</lpage>
          <pub-id pub-id-type="pmid">3499812</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Saito</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Matsunaga</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Matsumura</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Segawa</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Takakura</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Nagao</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Iinuma</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Miyachi</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Ichiyama</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Necrotizing fasciitis caused by Haemophilus influenzae type b in an elderly patient</article-title>
          <source>J Clin Microbiol</source>
          <year>2009</year>
          <volume>14</volume>
          <issue>3</issue>
          <fpage>852</fpage>
          <lpage>854</lpage>
          <pub-id pub-id-type="doi">10.1128/JCM.01196-08</pub-id>
          <pub-id pub-id-type="pmid">19116357</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Chalmers</surname>
            <given-names>C</given-names>
          </name>
          <article-title>Necrotising fasciitis complicating Haemophilus influenzae type b epiglottitis in an adult</article-title>
          <source>J Laryngol Otol</source>
          <year>2010</year>
          <volume>14</volume>
          <issue>7</issue>
          <fpage>807</fpage>
          <lpage>809</lpage>
          <pub-id pub-id-type="doi">10.1017/S0022215109992076</pub-id>
          <pub-id pub-id-type="pmid">19930753</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Lee</surname>
            <given-names>EY</given-names>
          </name>
          <name>
            <surname>Ip</surname>
            <given-names>WY</given-names>
          </name>
          <article-title>Necrotizing fasciitis of the extremity caused by Haemophilus influenzae serotype b in a healthy adult</article-title>
          <source>Clin Orthop Relat Res</source>
          <year>2010</year>
          <volume>14</volume>
          <issue>5</issue>
          <fpage>1436</fpage>
          <lpage>1439</lpage>
          <pub-id pub-id-type="doi">10.1007/s11999-009-1126-x</pub-id>
          <pub-id pub-id-type="pmid">19838646</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
